Peroxiredoxin distribution in the mouse brain with emphasis on neuronal populations affected in neurodegenerative disorders

Journal of Comparative Neurology

Volumn 520, Issue 2, 2012, Pages 258-280

  Goemaere, Julie ^a   Knoops, Bernard ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Antioxidant enzyme; Hippocampus; Immunohistochemistry; Motor neuron; Substantia nigra

Indexed keywords

DOPAMINE; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PEROXIREDOXIN 3; PEROXIREDOXIN 4; PEROXIREDOXIN 5; PEROXIREDOXIN 6;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CRANIAL NERVE; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; FEMALE; GLIA; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA2 REGION; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE CELL; NONHUMAN; OLFACTORY BULB; OXIDATIVE STRESS; PONS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PYRAMIDAL NERVE CELL; RED NUCLEUS; SPINAL CORD MOTONEURON; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; BRAIN; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIREDOXINS; PROTEIN ISOFORMS; RECOMBINANT PROTEINS;

EID: 82355161615     PISSN: 00219967     EISSN: 10969861     Source Type: Journal    
DOI: 10.1002/cne.22689     Document Type: Article

References (74)

1. Aon-Bertolino ML, Romero JI, Galeano P, Holubiec M, Badorrey MS, Saraceno GE, Hanschmann EM, Lillig CH, Capani F. 2011. Thioredoxin and glutaredoxin system proteins-immunolocalization in the rat central nervous system. Biochim Biophys Acta 1810: 93-110.
2. Barber SC, Mead RJ, Shaw PJ. 2006. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 1762: 1051-1067.
3. Baudry M, Yao Y, Simmons D, Liu J, Bi X. 2003. Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: immunohistochemical observations of microglia and astroglia. Exp Neurol 184: 887-903.
4. Butterfield DA, Perluigi M, Sultana R. 2006. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 545: 39-50.
5. Caron E, Sachot C, Prevot V, Bouret SG. 2010. Distribution of leptin-sensitive cells in the postnatal and adult mouse brain. J Comp Neurol 518: 459-476.
6. Chang TS, Cho CS, Park S, Yu S, Kang SW, Rhee SG. 2004. Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem 279: 41975-41984.
7. Cox AG, Winterbourn CC, Hampton MB. 2010. Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. Biochem J 425: 313-325.
8. Dammeyer P, Arnér ES. 2011. Human Protein Atlas of redox systems - what can be learnt? Biochim Biophys Acta 1810: 111-138.
9. De Simoni S, Goemaere J, Knoops B. 2008. Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+. Neurosci Lett 433: 219-224.
10. Drechsel DA, Patel M. 2008. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic Biol Med 44: 1873-1886.
11. Drechsel DA, Patel M. 2010. Respiration-dependent H2O2 removal in brain mitochondria via the thioredoxin/peroxiredoxin system. J Biol Chem 285: 27850-27858.
12. Droge W. 2002. Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95.
13. Fang J, Nakamura T, Cho DH, Gu Z, Lipton SA. 2007. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. Proc Natl Acad Sci U S A 104: 18742-18747.
14. Franklin KBJ, Paxinos G. 2007. The mouse brain in stereotaxic coordinates, 3rd ed. San Diego: Academic Press, Elsevier.
15. Frisoni GB, Ganzola R, Canu E, Rub U, Pizzini FB, Alessandrini F, Zoccatelli G, Beltramello A, Caltagirone C, Thompson PM. 2008. Mapping local hippocampal changes in Alzheimer's disease and normal ageing with MRI at 3 Tesla. Brain 131: 3266-3276.
16. Fujii J, Ikeda Y. 2002. Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep 7: 123-130.
17. Godoy JR, Funke M, Ackermann W, Haunhorst P, Oesteritz S, Capani F, Elsasser HP, Lillig CH. 2011. Redox atlas of the mouse Immunohistochemical detection of glutaredoxin-, peroxiredoxin-, and thioredoxin-family proteins in various tissues of the laboratory mouse. Biochim Biophys Acta 1810: 2-92.
18. Gonzalez-Hernandez T, Afonso-Oramas D, Cruz-Muros I. 2009. Phenotype, compartmental organization and differential vulnerability of nigral dopaminergic neurons. J Neural Transm Suppl: 21-37.
19. Halliwell B. 2006. Oxidative stress and neurodegeneration: where are we now? J Neurochem 97: 1634-1658.
20. Haridas V, Ni J, Meager A, Su J, Yu GL, Zhai Y, Kyaw H, Akama KT, Hu J, Van Eldik LJ, Aggarwal BB. 1998. TRANK, a novel cytokine that activates NF-kappa B and c-Jun N-terminal kinase. J Immunol 161: 1-6.
21. Harsan LA, Steibel J, Zaremba A, Agin A, Sapin R, Poulet P, Guignard B, Parizel N, Grucker D, Boehm N, Miller RH, Ghandour MS. 2008. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci 28: 14189-14201.
22. Hattori F, Murayama N, Noshita T, Oikawa S. 2003. Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. J Neurochem 86: 860-868.
23. Hirsch EC. 1994. Biochemistry of Parkinson's disease with special reference to the dopaminergic systems. Mol Neurobiol 9: 135-142.
24. Hirsch E, Graybiel AM, Agid YA. 1988. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334: 345-348.
25. Ichimiya S, Davis JG, O'Rourke DM, Katsumata M, Greene MI. 1997. Murine thioredoxin peroxidase delays neuronal apoptosis and is expressed in areas of the brain most susceptible to hypoxic and ischemic injury. DNA Cell Biol 16: 311-321.
26. Iuchi Y, Okada F, Tsunoda S, Kibe N, Shirasawa N, Ikawa M, Okabe M, Ikeda Y, Fujii J. 2009. Peroxiredoxin 4 knockout results in elevated spermatogenic cell death via oxidative stress. Biochem J 419: 149-158.
27. Jarvela S, Rantala I, Rodriguez A, Kallio H, Parkkila S, Kinnula VL, Soini Y, Haapasalo H. 2010. Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors. BMC Cancer 10: 104.
28. Jin DY, Chae HZ, Rhee SG, Jeang KT. 1997. Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. J Biol Chem 272: 30952-30961.
29. Jin MH, Lee YH, Kim JM, Sun HN, Moon EY, Shong MH, Kim SU, Lee SH, Lee TH, Yu DY, Lee DS. 2005. Characterization of neural cell types expressing peroxiredoxins in mouse brain. Neurosci Lett 381: 252-257.
30. Julien JP. 2001. Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell 104: 581-591.
31. Kim SH, Fountoulakis M, Cairns N, Lubec G. 2001. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl 223-235.
32. Kim SU, Hwang CN, Sun HN, Jin MH, Han YH, Lee H, Kim JM, Kim SK, Yu DY, Lee DS, Lee SH. 2008. Peroxiredoxin I is an indicator of microglia activation and protects against hydrogen peroxide-mediated microglial death. Biol Pharm Bull 31: 820-825.
33. Kimoto-Kinoshita S, Nishida S, Tomura TT. 1999. Age-related change of antioxidant capacities in the cerebral cortex and hippocampus of stroke-prone spontaneously hypertensive rats. Neurosci Lett 273: 41-44.
34. Kitada M, Rowitch DH. 2006. Transcription factor co-expression patterns indicate heterogeneity of oligodendroglial subpopulations in adult spinal cord. Glia 54: 35-46.
35. Krapfenbauer K, Engidawork E, Cairns N, Fountoulakis M, Lubec G. 2003. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res 967: 152-160.
36. Lazarenko RM, Milner TA, Depuy SD, Stornetta RL, West GH, Kievits JA, Bayliss DA, Guyenet PG. 2009. Acid sensitivity and ultrastructure of the retrotrapezoid nucleus in Phox2b-EGFP transgenic mice. J Comp Neurol 517: 69-86.
37. Lee VM, Page CD, Wu HL, Schlaepfer WW. 1984. Monoclonal antibodies to gel-excised glial filament protein and their reactivities with other intermediate filament proteins. J Neurochem 42: 25-32.
38. Lee TH, Kim SU, Yu SL, Kim SH, Park DS, Moon HB, Dho SH, Kwon KS, Kwon HJ, Han YH, Jeong S, Kang SW, Shin HS, Lee KK, Rhee SG, Yu DY. 2003. Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. Blood 101: 5033-5038.
39. Lee YM, Park SH, Shin DI, Hwang JY, Park B, Park YJ, Lee TH, Chae HZ, Jin BK, Oh TH, Oh YJ. 2008. Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease. J Biol Chem 283: 9986-9998.
40. Li L, Shoji W, Takano H, Nishimura N, Aoki Y, Takahashi R, Goto S, Kaifu T, Takai T, Obinata M. 2007. Increased susceptibility of MER5 (peroxiredoxin III) knockout mice to LPS-induced oxidative stress. Biochem Biophys Res Commun 355: 715-721.
41. Lippoldt A, Padilla CA, Gerst H, Andbjer B, Richter E, Holmgren A, Fuxe K. 1995. Localization of thioredoxin in the rat brain and functional implications. J Neurosci 15: 6747-6756.
42. Lu JL, Vallat JM, Pollard JD, Knoops B, Ouvrier R. 2006. Expression of the antioxidant enzyme peroxiredoxin 5 in the human peripheral nervous system. J Peripher Nerv Syst 11: 318-324.
43. Manevich Y, Sweitzer T, Pak JH, Feinstein SI, Muzykantov V, Fisher AB. 2002. 1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage. Proc Natl Acad Sci U S A 99: 11599-11604.
44. Matsumoto A, Okado A, Fujii T, Fujii J, Egashira M, Niikawa N, Taniguchi N. 1999. Cloning of the peroxiredoxin gene family in rats and characterization of the fourth member. FEBS Lett 443: 246-250.
45. Mattiasson G, Friberg H, Hansson M, Elmer E, Wieloch T. 2003. Flow cytometric analysis of mitochondria from CA1 and CA3 regions of rat hippocampus reveals differences in permeability transition pore activation. J Neurochem 87: 532-544.
46. Mizusawa H, Ishii T, Bannai S. 2000. Peroxiredoxin I (macrophage 23 kDa stress protein) is highly and widely expressed in the rat nervous system. Neurosci Lett 283: 57-60.
47. Mullen RJ, Buck CR, Smith AM. 1992. NeuN, a neuronal specific nuclear protein in vertebrates. Development 116: 201-211.
48. Muramatsu Y, Kurosaki R, Watanabe H, Michimata M, Matsubara M, Imai Y, Araki T. 2003. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice. Glia 42: 307-313.
49. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH, Van Etten RA. 2003. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424: 561-565.
50. Oberley TD, Verwiebe E, Zhong W, Kang SW, Rhee SG. 2001. Localization of the thioredoxin system in normal rat kidney. Free Radic Biol Med 30: 412-424.
51. Pardo CA, Xu Z, Borchelt DR, Price DL, Sisodia SS, Cleveland DW. 1995. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci U S A 92: 954-958.
52. Pineau I, Lacroix S. 2007. Proinflammatory cytokine synthesis in the injured mouse spinal cord: multiphasic expression pattern and identification of the cell types involved. J Comp Neurol 500: 267-285.
53. Power JH, Asad S, Chataway TK, Chegini F, Manavis J, Temlett JA, Jensen PH, Blumbergs PC, Gai WP. 2008. Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer's disease pathology. Acta Neuropathol 115: 611-622.
54. Qu D, Rashidian J, Mount MP, Aleyasin H, Parsanejad M, Lira A, Haque E, Zhang Y, Callaghan S, Daigle M, Rousseaux MW, Slack RS, Albert PR, Vincent I, Woulfe JM, Park DS. 2007. Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron 55: 37-52.
55. Rhee SG, Chae HZ, Kim K. 2005a. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38: 1543-1552.
56. Rhee SG, Kang SW, Jeong W, Chang TS, Yang KS, Woo HA. 2005b. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr Opin Cell Biol 17: 183-189.
57. Rybnikova E, Damdimopoulos AE, Gustafsson JA, Spyrou G, Pelto-Huikko M. 2000. Expression of novel antioxidant thioredoxin-2 in the rat brain. Eur J Neurosci 12: 1669-1678.
58. Sanchez-Madrid F, Simon P, Thompson S, Springer TA. 1983. Mapping of antigenic and functional epitopes on the alpha- and beta-subunits of two related mouse glycoproteins involved in cell interactions, LFA-1 and Mac-1. J Exp Med 158: 586-602.
59. Sarafian TA, Verity MA, Vinters HV, Shih CC, Shi L, Ji XD, Dong L, Shau H. 1999. Differential expression of peroxiredoxin subtypes in human brain cell types. J Neurosci Res 56: 206-212.
60. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH. 2003. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 23: 3394-3406.
61. Sorolla MA, Reverter-Branch, Tamarit J, Ferrer I, Ros J, Cabiscol E. 2008. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med 45: 667-678.
62. Springer TA. 1981. Monoclonal antibody analysis of complex biological systems. Combination of cell hybridization and immunoadsorbents in a novel cascade procedure and its application to the macrophage cell surface. J Biol Chem 256: 3833-3839.
63. Springer T, Galfre G, Secher DS, Milstein C. 1979. Mac-1: a macrophage differentiation antigen identified by monoclonal antibody. Eur J Immunol 9: 301-306.
64. Strey CW, Spellman D, Stieber A, Gonatas JO, Wang X, Lambris JD, Gonatas NK. 2004. Dysregulation of stathmin, a microtubule-destabilizing protein, and up-regulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model of familial amyotrophic lateral sclerosis. Am J Pathol 165: 1701-1718.
65. Trépanier G, Furling D, Puymirat J, Mirault ME. 1996. Immunocytochemical localization of seleno-glutathione peroxidase in the adult mouse brain. Neurosci 75: 231-243.
66. Trujillo M, Ferrer-Sueta G, Thomson L, Flohe L, Radi R. 2007. Kinetics of peroxiredoxins and their role in the decomposition of peroxynitrite. Subcell Biochem 44: 83-113.
67. Wang HL, Morales M. 2008. Corticotropin-releasing factor binding protein within the ventral tegmental area is expressed in a subset of dopaminergic neurons. J Comp Neurol 509: 302-318.
68. Wang MX, Wei AQ, Yuan J, Clippe A, Bernard A, Knoops B, Murrell GAC. 2001. Antioxidant enzyme peroxiredoxin 5 is upregulated in degenerative human tendon. Biochem Biophys Res Commun 284: 667-673.
69. Wang Y, Feinstein SI, Manevich Y, Ho YS, Fisher AB. 2004. Lung injury and mortality with hyperoxia are increased in peroxiredoxin 6 gene-targeted mice. Free Radic Biol Med 37: 1736-1743.
70. Wilde GJ, Pringle AK, Wright P, Iannotti F. 1997. Differential vulnerability of the CA1 and CA3 subfields of the hippocampus to superoxide and hydroxyl radicals in vitro. J Neurochem 69: 883-886.
71. Wood ZA, Poole LB, Karplus PA. 2003. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 300: 650-653.
72. Yang HY, Kwon J, Cho EJ, Choi HI, Park C, Park HR, Park SH, Chung KJ, Ryoo ZY, Cho KO, Lee TH. 2010. Proteomic analysis of protein expression affected by peroxiredoxin V knock-down in hypoxic kidney. J Proteome Res 9: 4003-4015.
73. Zhao W, Fan GC, Zhang ZG, Bandyopadhyay A, Zhou X, Kranias EG. 2009. Protection of peroxiredoxin II on oxidative stress-induced cardiomyocyte death and apoptosis. Basic Res Cardiol 104: 377-389.
74. Zhou Q, Wang S, Anderson DJ. 2000. Identification of a novel family of oligodendrocyte lineage-specific basic helix-loop-helix transcription factors. Neuron 25: 331-343.